Entyvio® (vedolizumab) UK Website
Entyvio is a treatment for adults with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease, two types of inflammatory bowel disease (IBD).
This website contains useful information about Entyvio for different audiences: there is a section with product and prescribing information for healthcare professionals, a section for patients who have been prescribed Entyvio, a further section with IBD information for the general public and a section containing resources for journalists and the media.
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda by e-mail at DSO-UK@takeda.com